- Previous Close
122.52 - Open
121.96 - Bid 118.47 x 100
- Ask 119.01 x 100
- Day's Range
118.27 - 122.22 - 52 Week Range
55.25 - 173.25 - Volume
1,381,121 - Avg. Volume
1,030,650 - Market Cap (intraday)
11.326B - Beta (5Y Monthly) 0.81
- PE Ratio (TTM)
158.35 - EPS (TTM)
0.75 - Earnings Date Oct 30, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
188.73
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
www.sarepta.comRecent News: SRPT
View MorePerformance Overview: SRPT
Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SRPT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SRPT
View MoreValuation Measures
Market Cap
11.33B
Enterprise Value
11.24B
Trailing P/E
158.35
Forward P/E
9.20
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.71
Price/Book (mrq)
10.52
Enterprise Value/Revenue
7.47
Enterprise Value/EBITDA
92.51
Financial Highlights
Profitability and Income Statement
Profit Margin
3.14%
Return on Assets (ttm)
0.73%
Return on Equity (ttm)
5.20%
Revenue (ttm)
1.5B
Net Income Avi to Common (ttm)
47.3M
Diluted EPS (ttm)
0.75
Balance Sheet and Cash Flow
Total Cash (mrq)
1.46B
Total Debt/Equity (mrq)
128.78%
Levered Free Cash Flow (ttm)
-408.09M
Research Analysis: SRPT
View MoreCompany Insights: SRPT
SRPT does not have Company Insights
Research Reports: SRPT
View MoreLowering target price to $98.00
SAREPTA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $98.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $101.00
SAREPTA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $101.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $102.00
SAREPTA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $102.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetRaising target price to $113.00
SAREPTA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $113.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target